Role of insulin-like growth factor binding proteins in 1α,25- dihydroxyvitamin D3-induced growth inhibition of human prostate cancer cells

Prostate

Volumn 64, Issue 1, 2005, Pages 9-19

  Stewart, LaMonica V ^a   Weigel, Nancy L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

IGF binding protein; Prostate; Vitamin D

Indexed keywords

CALCITRIOL; MESSENGER RNA; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN SECRETION; UPREGULATION; WESTERN BLOTTING;

ANDROGENS; BLOOD PROTEINS; CALCITRIOL; CALCIUM CHANNEL AGONISTS; CELL DIVISION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; PROSTATIC NEOPLASMS; RNA, MESSENGER; UP-REGULATION;

EID: 19544391427     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20212     Document Type: Article

References (40)

1. Society AC. Cancer facts & figures 2003; 2003.
2. Santen R. Clinical review 37: Endocrine treatment of prostate cancer. J Clin Endocrinol Metab 1992;75:685-689.
3. Haussler M, Mangelsdorf DJ, Komm BS, Terpening CM, Yamazaki K, Allegretto EA, Baker AR, Shine J, McDonnell TJ, Hughes M, Weigel NL, O'Malley BW, Pike JW. Molecular biology of the vitamin D hormone. In: Recent progress in hormone research. Vol 44. New York: Academic Press, Inc.; 1988. pp 263-305.
4. Blutt SE, Allegretto EA, Pike JW, Weigel NL. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 1997;138:1491-1497.
5. Skowronski RJ, Peehl DM, Feldman D, Schwartz GG. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:1952-1960.
6. Zhao XY, Peehl DM, Navone NM, Feldman D. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 2000;141:2548-2556.
7. Polek TC, Stewart LV, Ryu EJ, Cohen MB, Allegretto EA, Weigel NL. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 2003;144:50-60.
8. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res 2000;60:779-782.
9. Polek TC, Murthy S, Blutt SE, Boehm MF, Zou A, Weigel NL, Allegretto EA. Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate 2001;49:224-233.
10. Zhuang SH, Burnstein KL. Antiproliferative effect of 1alpha,25- dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998;139:1197-1207.
11. Yang E, Burnstein K. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 2003;278: 46862-46868.
12. Guzey M, Kitada S, Reed J. Apoptosis induction by 1a,25-dihydroxyvitamin d3 in prostate cancer. Mol Cancer Ther 2002;1:667-677.
13. Blutt SE, McDonnell TJ, Polek TC, Weigel NL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 2000;141:10-17.
14. Murthy S, Weigel N. 1a,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate 2003;59:282-291.
15. Guo Y, Kyprianou N. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ 1998;9:185-193.
16. Bartek J, Lucas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 2001;490:117-122.
17. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Phys 2000;183:1-9.
18. Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ. Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: Possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 2003;144:2319-2324.
19. Huynh H, Pollak M, Zhang JC. Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089. Int J Oncol 1998;13:137-143.
20. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 2001;165:1319-1324.
21. Miyake H, Pollak M, Cleave ME. Castration-induced upregulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 2000;60:3058-3064.
22. Moore MG, Wetterau LA, Francis MJ, Peehl DM, Cohen P. Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer 2003;105:14-19.
23. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997;272:12181-12188.
24. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 1996;56:1545-1550.
25. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA 1984;81:1991-1995.
26. Goossens K, Esquenet M, Swinnen JV, Manin M, Rombauts W, Verhoeven G. Androgens decrease and retinoids increase the expression of insulin-like growth factor-binding protein-3 in LNcaP prostatic adenocarcinoma cells. Mol Cell Endocrinol 1999;155:9-18.
27. Zhao XY, Ly LH, Peehl DM, Feldman D. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 1997;138:3290-3298.
28. Fanayan S, Firth SM, Butt AJ, Baxter RC. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta) and the type II TGF-beta receptor. J Biol Chem 2000;275:39146-39151.
29. Velez-Yanguas MC, Kalebic T, Maggi M, Kappel CC, Letterio J, Uskokovic M, Helman LJ. 1 alpha, 25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line. J Clin Endocrinol Metab 1996;81:93-99.
30. Scharla SH, Strong DD, Rosen C, Mohan S, Holick M, Baylink DJ, Linkhart TA. 1,25-Dihydroxyvitamin D3 increases secretion of insulin-like growth factor binding protein-4 (IGFBP-4) by human osteoblast-like cells in vitro and elevates IGFBP-4 serum levels in vivo. J Clin Endocrinol Metab 1993;77:1190-1197.
31. Rozen F, Pollak M. Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Int J Oncol 1999;15:589-594.
32. Oh YS, Kim EJ, Schaffer BS, Kang YH, Binderup L, MacDonald RG, Park JH. Synthetic low-calcaemic vitamin D(3) analogues inhibit secretion of insulin-like growth factor II and stimulate production of insulin-like growth factor-binding protein-6 in conjunction with growth suppression of HT-29 colon cancer cells. Mol Cell Endocrinol 2001;183:141-149.
33. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Cleave ME. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003;63:3575-3584.
34. Sprenger CC, Peterson A, Lance R, Ware JL, Drivdahl RH, Plymate SR. Regulation of proliferation of prostate epithelial cells by 1,25- dihydroxyvitamin D3 is accompanied by an increase in insulin-like growth factor binding protein-3. J Endocrinol 2001;170:609-618.
35. Nickerson T, Huynh H. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J Endocrinol 1999;160:223-229.
36. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 2004;59:243-251.
37. Peng L, Malloy P, Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 2004;18: 1109-1119.
38. Marcelli M, Haidacher SJ, Plymate SR, Birnbaum RS. Altered growth and insulin-like growth factor-binding protein-3 production in PC-3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology 1995;136:1040-1048.
39. Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM, Slawin KM. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 2002;20:833-841.
40. Cohen P, Nunn SE, Peehl DM. Transforming growth factor-beta induces growth inhibition and IGF-binding protein-3 production in prostatic stromal cells: Abnormalities in cells cultured from benign prostatic hyperplasia tissues. J Endocrinol 2000;164:215-223.